Voyager Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 171m | 37.4m | 40.9m | 250m | 69.2m | 55.8m | 53.7m |
| % growth | 64 % | (78 %) | 9 % | 511 % | (72 %) | (19 %) | (4 %) |
| EBITDA | 31.2m | (73.6m) | (50.8m) | 126m | (81.6m) | (116m) | (114m) |
| % EBITDA margin | 18 % | (197 %) | (124 %) | 51 % | (118 %) | (208 %) | (212 %) |
| Profit | 36.7m | (71.2m) | (46.4m) | 132m | (80.2m) | (119m) | (125m) |
| % profit margin | 21 % | (190 %) | (113 %) | 53 % | (116 %) | (213 %) | (232 %) |
| EV / revenue | 0.5x | -0.4x | 2.9x | 0.6x | 0.8x | 1.3x | -1.5x |
| EV / EBITDA | 2.8x | 0.2x | -2.3x | 1.1x | -0.7x | -0.6x | 0.7x |
| R&D budget | 109m | 73.8m | 60.8m | 92.2m | - | - | - |
| R&D % of revenue | 64 % | 197 % | 149 % | 37 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$45.0m | Series A | ||
$60.0m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | $100m | Post IPO Equity |
* | $39.0m | Post IPO Equity | |
* | $136m | Post IPO Debt | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | CAD143m | ||
Related Content
Recent News about Voyager Therapeutics
EditVoyager Therapeutics is a biotechnology company focused on developing transformative genetic medicines for neurological diseases. The company operates in the healthcare and biotechnology market, specifically targeting conditions that affect the central nervous system, such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Voyager Therapeutics serves a diverse range of clients, including patients suffering from severe neurological conditions, healthcare providers, and research institutions. The company’s primary goal is to create innovative treatments that can cross the blood-brain barrier, a critical challenge in treating brain-related diseases. This is achieved through their proprietary AAV (adeno-associated virus) capsid discovery platform, which has shown promising results in preclinical studies for delivering genetic material directly to the brain via intravenous dosing.
The business model of Voyager Therapeutics revolves around research and development (R&D) of these genetic medicines. They invest heavily in scientific research to discover and develop new treatments. Revenue is generated through a combination of partnerships with larger pharmaceutical companies, licensing agreements, and potentially, future sales of approved therapies. By collaborating with established firms, Voyager can leverage additional resources and expertise to accelerate the development and commercialization of their treatments.
Voyager Therapeutics is driven by a patient-first philosophy, emphasizing the importance of creating meaningful and transformative treatments. The company values collaboration, innovation, and community, fostering a work environment where cross-functional teams can thrive and break through traditional barriers in medical research.
In summary, Voyager Therapeutics is a pioneering biotech firm dedicated to advancing genetic medicines for neurological diseases, with a strong focus on innovative delivery methods and collaborative partnerships.
Keywords: Biotechnology, Neurological Diseases, Genetic Medicines, ALS, Central Nervous System, AAV Capsid, Blood-Brain Barrier, Research and Development, Partnerships, Innovation.